FRTX-02, a selective and potent inhibitor of DYRK1A, modulates inflammatory pathways in mouse models of psoriasis and atopic dermatitis

Hämmerle, 2008, The spatio-temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development, Eur. J. Neurosci., 27, 1061, 10.1111/j.1460-9568.2008.06092.x Ogawa, 2010, Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A, Nat. Commun., 1, 86, 10.1038/ncomms1090 Duchon, 2016, DYRK1A, a dosage-sensitive gene involved in neurodevelopmental disorders, is a target for drug development in Down syndrome, Front. Behav. Neurosci., 10, 104, 10.3389/fnbeh.2016.00104 Wegiel, 2008, The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome, Acta Neuropathol., 116, 391, 10.1007/s00401-008-0419-6 Arbones, 2019, DYRK1A and cognition: a lifelong relationship, Pharmacol. Ther., 194, 199, 10.1016/j.pharmthera.2018.09.010 Kumar, 2021, DYRK1A inhibitors as potential therapeutics for β-cell regeneration for diabetes, J. Med. Chem., 64, 2901, 10.1021/acs.jmedchem.0c02050 Rammohan, 2022, The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target, Oncogene, 41, 2003, 10.1038/s41388-022-02245-6 Antonarakis, 2020, Down syndrome, Nat. Rev. Dis. Prim., 6 Bull, 2020, Down syndrome, N. Engl. J. Med., 382, 2344, 10.1056/NEJMra1706537 Hasle, 2016, Low risk of solid tumors in persons with Down syndrome, Genet. Med., 18, 1151, 10.1038/gim.2016.23 O'Leary, 2018, Early death and causes of death of people with Down syndrome: a systematic review, J. Appl. Res. Intellect. Disabil., 31, 687, 10.1111/jar.12446 Madani, 2021, Adalimumab therapy in a patient with psoriasis, Down syndrome, and concomitant hepatitis B virus infection, Biologics, 15, 375 Foley, 2019, Arthropathy of Down syndrome: an under-diagnosed inflammatory joint disease that warrants a name change, RMD Open, 5, 10.1136/rmdopen-2018-000890 Araya, 2019, Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity, Proc. Natl. Acad. Sci. U. S. A., 116, 24231, 10.1073/pnas.1908129116 Lambert, 2022, Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity, Sci. Transl. Med., 14, 10.1126/scitranslmed.abi4888 Pellegrini, 2012, Down syndrome, autoimmunity and T regulatory cells, Clin. Exp. Immunol., 169, 238, 10.1111/j.1365-2249.2012.04610.x Macian, 2005, NFAT proteins: key regulators of T-cell development and function, Nat. Rev. Immunol., 5, 472, 10.1038/nri1632 Gwack, 2006, A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT, Nature, 441, 646, 10.1038/nature04631 Jarhad, 2018, Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics, J. Med. Chem., 61, 9791, 10.1021/acs.jmedchem.8b00185 Khor, 2015, The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells, Elife, 4, 10.7554/eLife.05920 Shaw, 2017, Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus, Bioorg Med Chem Lett, 27, 2617, 10.1016/j.bmcl.2017.03.037 Shaw, 1988, Identification of a putative regulator of early T cell activation genes, Science, 241, 4972, 10.1126/science.3260404 Chow, 1999, Requirement for transcription factor NFAT in interleukin-2 expression, Mol. Cell Biol., 19, 2300, 10.1128/MCB.19.3.2300 Dienz, 2007, Accumulation of NFAT mediates IL-2 expression in memory, but not naïve, CD4+ T cells, Proc. Natl. Acad. Sci. U. S. A., 104, 7175, 10.1073/pnas.0610442104 Rooney, 1995, Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation, Mol. Cell Biol., 15, 6299, 10.1128/MCB.15.11.6299 Abbas, 2018, Revisiting IL-2: biology and therapeutic prospects, Sci Immunol, 3, 10.1126/sciimmunol.aat1482 Pinto, 2018, A network map of IL-33 signaling pathway, J Cell Commun Signal, 12, 615, 10.1007/s12079-018-0464-4 Oboki, 2010, IL-33 is a crucial amplifier of innate rather than acquired immunity, Proc. Natl. Acad. Sci. U. S. A., 107, 18581, 10.1073/pnas.1003059107 Dong, 2021, IL-33 in rheumatic diseases, Front. Med., 8, 10.3389/fmed.2021.739489 Espinosa-Riquer, 2020, Signal transduction pathways activated by innate immunity in mast cells: translating sensing of changes into specific responses, Cells, 9, 10.3390/cells9112411 Adachi, 1998, Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function, Immunity, 9, 143, 10.1016/S1074-7613(00)80596-8 Griesenauer, 2017, The ST2/IL-33 Axis in immune cells during inflammatory diseases, Front. Immunol., 8, 10.3389/fimmu.2017.00475 Pei, 2014, Emerging role of interleukin-33 in autoimmune diseases, Immunology, 141, 9, 10.1111/imm.12174 Janssens, 2002, Regulation of interleukin-1- and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88, Curr. Biol., 12, 467, 10.1016/S0960-9822(02)00712-1 de Arras, 2013, Limiting of the innate immune response by SF3A-dependent control of MyD88 alternative mRNA splicing, PLoS Genet., 9, 10.1371/journal.pgen.1003855 Saikh, 2021, MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity, Immunol. Res., 69, 117, 10.1007/s12026-021-09188-2 de Graaf, 2006, The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site, BMC Biochem., 7, 7, 10.1186/1471-2091-7-7 Hu, 2021, The role of helper T cells in psoriasis, Front. Immunol., 12, 10.3389/fimmu.2021.788940 van der Fits, 2009, Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis, J. Immunol., 182, 5836, 10.4049/jimmunol.0802999 Suárez-Fariñas, 2013, Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis, J. Allergy Clin. Immunol., 132, 361, 10.1016/j.jaci.2013.04.046 Martel, 2016, Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis, Exp. Dermatol., 25, 453, 10.1111/exd.12967 Noda, 2015, The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization, J. Allergy Clin. Immunol., 136, 1254, 10.1016/j.jaci.2015.08.015 Sanyal, 2019, Atopic dermatitis in African American patients is T H 2/T H 22-skewed with T H 1/T H 17 attenuation, Ann. Allergy Asthma Immunol., 122, 99, 10.1016/j.anai.2018.08.024 Brunner, 2018, Early-onset pediatric atopic dermatitis is characterized by T H 2/T H 17/T H 22-centered inflammation and lipid alterations, J. Allergy Clin. Immunol., 141, 2094, 10.1016/j.jaci.2018.02.040 Tsoi, 2020, Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses, J. Allergy Clin. Immunol., 145, 1406, 10.1016/j.jaci.2019.11.047 Savinko, 2012, IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors, J. Invest. Dermatol., 132, 1392, 10.1038/jid.2011.446 Li, 2017, Experimental atopic dermatitis depends on IL-33R signaling via MyD88 in dendritic cells, Cell Death Dis., 8 Chen, 2019, Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis, Sci. Transl. Med., 11, 10.1126/scitranslmed.aax2945 Suto, 1999, NC/Nga mice: a mouse model for atopic dermatitis, Int. Arch. Allergy Immunol., 120, 70, 10.1159/000053599 Burns, 2003, Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4, J. Exp. Med., 197, 263, 10.1084/jem.20021790 Lee, 2020, NF-κB mediates lipopolysaccharide-induced alternative pre-mRNA splicing of MyD88 in mouse macrophages, J. Biol. Chem., 295, 6236, 10.1074/jbc.RA119.011495 Campanati, 2021, Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches, Biomedicines, 9, 10.3390/biomedicines9111511 Tesmer, 2008, Th17 cells in human disease, Immunol. Rev., 223, 87, 10.1111/j.1600-065X.2008.00628.x Marson, 2021, Newer therapies in psoriasis, Med. Clin., 105, 627 Horwitz, 2019, Rebalancing immune homeostasis to treat autoimmune diseases, Trends Immunol., 40, 888, 10.1016/j.it.2019.08.003